News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
December, 2023
December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Gemma Peters: This work is revolutionising how we think about meeting needs of patients and families at the end-of-life.
Photo from Gemma Peters/LinkedIn
Sep 20, 2023, 17:27

Gemma Peters: This work is revolutionising how we think about meeting needs of patients and families at the end-of-life.

Gemma Peters, CEO at Macmillan Cancer Support, recently shared a post by Social Finance on LinkedIn, adding:

”This work is revolutionising how we think about meeting needs of patients and families at the end-of-life. This £36million fund is open to all partners, including NHS bodies, who have transformational ideas. Please share with relevant people in your networks.”

Quoting Social Finance’s post:

”Open to applications today: £36m fund for adult end-of-life care services.

Through social investment, partners can get up-front funding for transformational end-of-life care services for adults that’s only repayable if agreed outcomes are met, with no financial return. Macmillan Cancer Supportand Social Finance provide programme, financial and clinical expertise to design and support the funded services.

The social investment provided by Macmillan is not a grant or a loan, meaning that this funding source is open to all partners including NHS bodies. There are no interest charges and outcomes payments will never exceed the total service costs, funded in full by Macmillan.

Services invested in by the Macmillan fund to date are already demonstrating that the value of savings is greater than the service running costs, and we want to help others achieve this.

The £36m fund is now open to applications and the deadline is 31 October 2023.”

For the information click here.
Source: Gemma Peters/LinkedIn

cancer end-of-life care services Gemma Peters Macmillan Cancer Supportand Social Finance OncoDaily Oncology
Insight
Dec 9, 2023, 04:44
President Biden: It's good for the millions of Americans who can't afford their medications
Blog
Dec 9, 2023, 00:38
Thomas Hofmarcher: This is what a great panel discussion looks like!
Blog
Dec 9, 2023, 00:32
Zhiheng Xu: It's not just about how much statistics you know
Blog
Dec 9, 2023, 00:23
Priscilla Chan: Mark and I wrote our annual letter this year about how some of our earliest bets in science are letting us take advantage of this moment in AI
Blog
Dec 9, 2023, 00:18
David Fajgenbaum: 1 in 10 of us will develop a disease with no treatments
Career
Dec 8, 2023, 17:54
Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
Drugs
Dec 8, 2023, 17:50
Pure Biologics to test molecule PBA-0405 in project PB004 in a Phase 0 clinical trial in patients with solid tumors - The Antibody Society
Drugs
Dec 8, 2023, 17:46
Earle Burgess: Interested in new treatments being developed for advanced (urothelial) bladder cancer?
Insight
Dec 8, 2023, 17:40
Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
Career
Dec 8, 2023, 17:35
Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
Insight
Dec 8, 2023, 17:32
Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
Blog
Dec 8, 2023, 17:27
Tedros Adhanom Ghebreyesus: Gaza cannot afford to lose any more hospitals…
Insight
Positive
Societies
Career